Call for entries to Rainer Rudolph Foundation prizes

Closing date is 31 March

Young researchers who have completed an outstanding final thesis in the fields of protein biochemistry and biotechnology have another month to apply for a €1,000 Rainer Rudolph Foundation prize. Applications should be submitted to the Foundation in Germany by 31 March.

Friends, companions, former colleagues and staff of the late Professor Dr Rainer Rudolph established The Rainer Rudolph Foundation in 2011 to honour his scientific work. Prior to his death in 2009, Professor Rudolph was among the world’s leading protein biochemists as well as the co-founder of Scil Proteins, the company which now sponsors The Rainer Rudolph Foundation.


Dr Ulrike Fiedler, chief executive of the Foundation and Scil Proteins, said: ‘During his work, Professor Rudolph placed particular emphasis on linking scientific research with industrial applications and consequently, the foundation of Scil Proteins was a logical step for him. Through the years, we came to know and appreciate Professor Rudolph as a highly respected scientist and competent industrial partner. The Rainer Rudolph prizes have been established to encourage upcoming generations of scientists to excel in their work and therefore, I hope many young researchers in the fields of protein biochemistry and biotechnology will apply.’

You may also like

Manufacturing

Wacker acquires Scil Proteins Production

The transaction will create a leading microbial-based biopharmaceutical manufacturer
Ingredients

Scil Proteins receives EMA approval for commercial production of Reteplase

The recombinant protein will be produced in Halle, Germany
Research & Development

Scil Proteins signs partnership to research cancer therapies

Will work with Martin Luther University Halle-Wittenberg
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Pharmaceutical

CellCarta and Leica Biosystems expand companion disgnostic development model partnership

Building on a successful CDx joint development model in China, the pair will aim to bring the end-to-end development framework to global customers to help their customers streamline the path to global CDx commercialisation
Manufacturing

ystral opens ATEX-compliant trial centre in Germany to expand customer process development capacity

The new facility, based in Ballrechten-Dottingen, will be able to handle flammable and explosive media testing across pharma, coatings and food applications, with remote livestream access and in-house particle size and viscosity analysis
Subscribe now